CA2862692C - Derives de pyrrolopyridine et compositions de ceux-ci utiles en tant qu'antifibrotiques - Google Patents

Derives de pyrrolopyridine et compositions de ceux-ci utiles en tant qu'antifibrotiques Download PDF

Info

Publication number
CA2862692C
CA2862692C CA2862692A CA2862692A CA2862692C CA 2862692 C CA2862692 C CA 2862692C CA 2862692 A CA2862692 A CA 2862692A CA 2862692 A CA2862692 A CA 2862692A CA 2862692 C CA2862692 C CA 2862692C
Authority
CA
Canada
Prior art keywords
phenyl
methyl
amino
compound
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2862692A
Other languages
English (en)
Other versions
CA2862692A1 (fr
Inventor
Bijoy Panicker
Rama K. Mishra
Dawoon Jung
Lambertus J.W.M. Oehlen
Dong Sung Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of CA2862692A1 publication Critical patent/CA2862692A1/fr
Application granted granted Critical
Publication of CA2862692C publication Critical patent/CA2862692C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule structurale générale (I), et leurs dérivés pharmaceutiquement acceptables, tels que généralement décrits dans les classes et les sous-classes dans le présent document. La présente invention concerne en outre des compositions pharmaceutiques les comprenant, et des procédés d'utilisation associés pour le traitement de toute affection ou de toute maladie impliquant une fibrose anormale ou excessive.
CA2862692A 2012-01-26 2013-01-26 Derives de pyrrolopyridine et compositions de ceux-ci utiles en tant qu'antifibrotiques Active CA2862692C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261632582P 2012-01-26 2012-01-26
US61/632,582 2012-01-26
PCT/US2013/023324 WO2013112959A1 (fr) 2012-01-26 2013-01-26 Composés antifibrotiques et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2862692A1 CA2862692A1 (fr) 2013-08-01
CA2862692C true CA2862692C (fr) 2021-05-04

Family

ID=48873985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2862692A Active CA2862692C (fr) 2012-01-26 2013-01-26 Derives de pyrrolopyridine et compositions de ceux-ci utiles en tant qu'antifibrotiques

Country Status (15)

Country Link
US (4) US9040555B2 (fr)
EP (2) EP2807160B1 (fr)
JP (1) JP6152389B2 (fr)
CN (1) CN104136436B (fr)
AU (1) AU2013211888B2 (fr)
CA (1) CA2862692C (fr)
DK (1) DK2807160T3 (fr)
ES (1) ES2748873T3 (fr)
HK (1) HK1203502A1 (fr)
HU (1) HUE046368T2 (fr)
IL (2) IL233727A (fr)
IN (1) IN2014DN06869A (fr)
PL (1) PL2807160T3 (fr)
PT (1) PT2807160T (fr)
WO (1) WO2013112959A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597321B2 (en) * 2012-01-26 2017-03-21 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US9040555B2 (en) 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US20150105380A1 (en) * 2013-09-23 2015-04-16 Angion Biomedica Corp. Methods and uses of compounds for treating disease
CN104387385B (zh) * 2014-11-14 2016-03-23 苏州和健医药科技有限公司 6-羧酸甲酯-2-氧-7-氮杂吲哚及其制备方法与应用
CA3004595A1 (fr) * 2015-11-12 2017-05-18 Lg Chem, Ltd. Composition pharmaceutique contenant, en tant que principe actif, un derive ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one
EA038773B1 (ru) 2016-03-08 2021-10-18 Респиверт Лимитед Индольные производные и их применение в качестве ингибиторов протеинкиназы
BR112018075202A2 (pt) * 2016-06-07 2019-03-19 Dermavant Sciences GmbH formulação tópica e método de tratamento de uma condição dermatológica em um sujeito
AU2020386913A1 (en) * 2019-11-20 2022-06-02 Angion Biomedica Corp. Methods for treating inflammatory bowel disease
WO2022006277A1 (fr) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Méthodes de traitement de maladies rénales fibrotiques
WO2022006238A1 (fr) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Formes solides de (z)-méthyl 3-(((4-(n-méthyl-2-(4-méthylpipérazin-1-yl)acétamido)phényl)amino)(phényl)méthylène)-2-oxo-2, 3-dihydro-1h-pyrrolo[2,3-b]pyridine-6-carboxylate et des sels de celui-ci
WO2022006278A1 (fr) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Réduction de la fibrose et traitement de maladies, de troubles et d'états associés
WO2022165092A1 (fr) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Méthodes de traitement de maladies fibrotiques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AU4685799A (en) 1998-06-17 2000-01-05 Geron Corporation Telomerase inhibitors
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
MXPA02010759A (es) 2000-05-02 2004-07-30 Sugen Inc Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
EP1581309A4 (fr) 2002-11-15 2009-07-29 Exelixis Inc Modulateurs de kinase
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008138232A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Dérivés pyrrolo-azotés hétérocycliques, leur préparation et leur utilisation pharmaceutique
WO2009042646A1 (fr) 2007-09-24 2009-04-02 Curis, Inc. Agents antiprolifératifs
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
WO2010088000A2 (fr) * 2009-02-02 2010-08-05 Angion Biomedica Corp. Composés antifibrotiques et leurs utilisations
WO2010144959A1 (fr) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues d'agents antifibrotiques
JP2011213697A (ja) 2010-04-02 2011-10-27 Astellas Pharma Inc アントラサイクリン化合物
US9040555B2 (en) 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US9597321B2 (en) * 2012-01-26 2017-03-21 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US20150105380A1 (en) 2013-09-23 2015-04-16 Angion Biomedica Corp. Methods and uses of compounds for treating disease

Also Published As

Publication number Publication date
AU2013211888B2 (en) 2017-08-31
WO2013112959A1 (fr) 2013-08-01
IN2014DN06869A (fr) 2015-05-22
US20180008581A1 (en) 2018-01-11
WO2013112959A9 (fr) 2015-01-15
EP3604307A1 (fr) 2020-02-05
JP6152389B2 (ja) 2017-06-21
WO2013112959A8 (fr) 2013-09-12
CN104136436B (zh) 2019-01-01
CN104136436A (zh) 2014-11-05
JP2015505543A (ja) 2015-02-23
EP2807160A1 (fr) 2014-12-03
US11504359B2 (en) 2022-11-22
EP2807160B1 (fr) 2019-07-24
IL251974B (en) 2020-08-31
IL233727A (en) 2017-05-29
CA2862692A1 (fr) 2013-08-01
ES2748873T3 (es) 2020-03-18
HK1203502A1 (en) 2015-10-30
US10195184B2 (en) 2019-02-05
US20200069662A1 (en) 2020-03-05
PL2807160T3 (pl) 2020-03-31
HUE046368T2 (hu) 2020-02-28
AU2013211888A1 (en) 2014-08-14
IL251974A0 (en) 2017-06-29
DK2807160T3 (da) 2019-10-14
EP2807160A4 (fr) 2014-12-24
US20140371234A1 (en) 2014-12-18
US20190125731A1 (en) 2019-05-02
US9040555B2 (en) 2015-05-26
PT2807160T (pt) 2019-10-28

Similar Documents

Publication Publication Date Title
US11504359B2 (en) Antifibrotic compounds and uses thereof
AU2020257075B2 (en) Methods and agents for treating disease
WO2010088000A2 (fr) Composés antifibrotiques et leurs utilisations
EP2292227B1 (fr) Derivés de pyrazole comme modulateurs de l'activité du facteur de croissance hépatocytaire (facteur de dispersion)
US20200071321A1 (en) Methods and uses of compounds for treating disease
CA2579240A1 (fr) Petits modulateurs moleculaires de l'activite de cytokines
US9597321B2 (en) Antifibrotic compounds and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180122